Adjuvant Endocrine Therapy Linked to Reduced Risk for Contralateral Breast Cancer in Community Setting (FREE)
By Amy Orciari Herman
Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS
Findings from a real-world analysis, reported in JAMA Oncology, confirm that adjuvant endocrine therapy lowers the risk for contralateral breast cancer in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 6, 2016 Category: Primary Care Source Type: news
Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer
Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy. (Source: Drug Development Technology)
Source: Drug Development Technology - September 29, 2016 Category: Pharmaceuticals Source Type: news
Compound Shows Promise as Next-Generation Prostate Cancer Therapy
Contact: Sarah Avery Phone: 919-660-1306 Email:sarah.avery@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) Monday, Aug. 8, 2016DURHAM, N.C. -- In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide.“Prostate cancer is the most p...
Source: DukeHealth.org: Duke Health Features - August 8, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Adjuvant Endocrine Therapy for ER-Positive Breast Cancer Adjuvant Endocrine Therapy for ER-Positive Breast Cancer
When should premenopausal women with ER-positive breast cancer receive standard adjuvant therapy plus adjuvant ovarian suppression? Read the latest guideline update here.Journal of Clinical Oncology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 8, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news
Neoadjuvant Endocrine Therapy Can Be Helpful in Breast CancerNeoadjuvant Endocrine Therapy Can Be Helpful in Breast Cancer
In women with localized estrogen receptor-positive breast cancer, neoadjuvant endocrine therapy - even as monotherapy - prompts response rates similar to those of combination chemotherapy but with lower toxicity, according to a meta-analysis by U.S. researchers. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 7, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Neoadjuvant endocrine therapy ‘a reasonable option’ for ER-positive breast cancer
Endocrine therapy should be reconsidered as a potential option in the neoadjuvant setting for localised oestrogen receptor-positive breast cancer, say the authors of a meta-analysis. (Source: MedWire News)
Source: MedWire News - July 1, 2016 Category: Consumer Health News Tags: Breast cancer Source Type: news
Factors affecting non-adherence to endocrine therapy
Publishing in the Journal of Asolescent and Young Adult Oncology, investigators conclude that tackling non-adherence in young women with breast cancer may come down to understanding and altering the way these patients perceive their treatment.
Clinical Oncology (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 3, 2016 Category: Endocrinology Source Type: news
Could statins prevent breast cancer returning?
Conclusion
The study aimed to identify biological pathways that could be the reason why some ER+ breast cancers relapse after oestrogen-blocking treatment.
It seems that one of the answers for treatment resistance lies in increased activity of cholesterol-producing pathways in the absence of oestrogen. The cholesterol molecules mimic oestrogen and stimulate further tumour growth.
The researchers hope that their research could potentially highlight a new pathway, which could be used as a target for therapeutic treatment in the future. Dr Lesley-Ann Martin from the research team told the media, "This is hugely significa...
Source: NHS News Feed - June 2, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news
ASCO's New Guideline for Endocrine Therapy in Breast CancerASCO's New Guideline for Endocrine Therapy in Breast Cancer
ASCO has a new guideline for the use of endocrine therapy in patients with hormone-receptor-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Widely used class of chemotherapy drugs does not lead to cognitive decline for women with breast cancer
UCLA Jonsson Comprehensive Cancer Center
Dr. Patricia Ganz
UCLA researchers have found that a commonly used chemotherapy drug does not appear to cause cognitive decline following treatment in women with breast cancer.
The study, published online today in JAMA Oncology, refutes concerns raised by research published in 2015 in the same journal. The earlier study, which focused on a small group of women, suggested that a class of drugs called anthracyclines might increase the risk for attention, perception and mood deficits, and other neuropsychological issues, as well as cognitive difficulties, such as memory loss.
Anthracy...
Source: UCLA Newsroom: Health Sciences - April 22, 2016 Category: Universities & Medical Training Source Type: news
Adjuvant endocrine therapy for premenopausal breast cancer patients should be individualized
Oncologists should take an individualized approach when making decisions about adjuvant endocrine therapies for premenopausal hormone receptor–positive, HER2-negative early breast cancer, suggests an... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 4, 2016 Category: Endocrinology Source Type: news
Neoadjuvant Endocrine Therapy Underused for Breast CancerNeoadjuvant Endocrine Therapy Underused for Breast Cancer
It does not work as fast as chemotherapy, but endocrine therapy increases breast conservation by downstaging disease. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Oncotype DX Testing Lets Some Breast Ca Patients Skip Chemo (CME/CE)
(MedPage Today) -- Low 21-gene score meant 98% disease-free survival with endocrine therapy alone (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 3, 2016 Category: Hematology Source Type: news
FDA expands Ibrance approval for metastatic breast cancer
Palbociclib (Ibrance, Pfizer), a cyclin-dependent kinase 4/6 inhibitor, is approved for use in combination with fulvestrant for the treatment of women with hormone receptor-positive, HER-2–negative metastatic breast cancer who progressed on endocrine therapy.
Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2016 Category: Endocrinology Source Type: news
What factors affect non-compliance with endocrine therapy among young women with breast cancer?
A new study of young women with hormone receptor-positive breast cancer showed that more than half did not believe endocrine therapy was essential. Research was completed at Harvard Medical School.
EurekAlert (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 18, 2016 Category: Endocrinology Source Type: news
